Literature DB >> 34130300

Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis.

Ben G L Vanneste1, Evert J Van Limbergen1, Tom A Marcelissen2, Joep G H van Roermund2, Ludy C Lutgens1, Carsten W K P Arnoldussen3, Philippe Lambin4, Matthias Oelke5.   

Abstract

OBJECTIVE: The purpose of this review was to summarize the current literature on the assessment and treatment of radiation urethritis and cystitis (RUC) for the development of an evidenced-based management algorithm.
MATERIAL AND METHODS: The PubMed/MEDLINE database was searched by a multidisciplinary group of experts in January 2021.
RESULTS: In total, 48 publications were identified. Three different types of RUC can be observed in clinical practice: inflammation-predominant, bleeding-predominant, and the combination of inflammation- and bleeding-RUC. There is no consensus on the optimal treatment of RUC. Inflammation-predominant RUC should be treated symptomatically based on the existence of bothersome storage or voiding lower urinary tract symptom as well as on pain. When bleeding-predominant RUC has occurred, hydration and hyperbaric oxygen therapy (HOT) should be used first and, if HOT is not available, oral drugs instead (sodium pentosane polysulfate, aminocaproic acid, immunokine WF 10, conjugated estrogene, or pentoxifylline + vitamin E). If local bleeding persists, focal therapy of bleeding vessels with a laser or electrocoagulation is indicated. In case of generalized bleeding, intravesical installation should be initiated (formalin, aluminium salts, and hyaluronic acid/chondroitin). Vessel embolization is a less invasive treatment with potentially less complications and good clinical outcomes. Open- or robot-assisted surgery is indicated in patients with permanent, life-threatening bleeding, or fistulae.
CONCLUSIONS: Treatment of RUC, if not self-limiting, should be done according to the type of RUC and in a stepwise approach. Conservative/medical treatment (oral and topic agents) should primarily be used before invasive (transurethral) treatments.
© 2021 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Prevention; Radiation cystitis; Radiation urethritis; Radiotherapy; Treatment

Mesh:

Year:  2021        PMID: 34130300     DOI: 10.1159/000515716

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

Review 1.  Understanding Molecular Mechanisms and Identifying Key Processes in Chronic Radiation Cystitis.

Authors:  Clément Brossard; Anne-Charlotte Lefranc; Jean-Marc Simon; Marc Benderitter; Fabien Milliat; Alain Chapel
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

2.  Voiding defects in acute radiation cystitis driven by urothelial barrier defect through loss of E-cadherin, ZO-1 and Uroplakin III.

Authors:  Bernadette M M Zwaans; Alexander L Carabulea; Sarah N Bartolone; Elijah P Ward; Michael B Chancellor; Laura E Lamb
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.